Paul Gillard

5.6k total citations · 1 hit paper
49 papers, 2.1k citations indexed

About

Paul Gillard is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Paul Gillard has authored 49 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 27 papers in Infectious Diseases and 9 papers in Immunology. Recurrent topics in Paul Gillard's work include Influenza Virus Research Studies (23 papers), Respiratory viral infections research (16 papers) and SARS-CoV-2 and COVID-19 Research (15 papers). Paul Gillard is often cited by papers focused on Influenza Virus Research Studies (23 papers), Respiratory viral infections research (16 papers) and SARS-CoV-2 and COVID-19 Research (15 papers). Paul Gillard collaborates with scholars based in Belgium, United States and United Kingdom. Paul Gillard's co-authors include Brigitte Cheuvart, Htay Htay Han, François Roman, Shabir A. Madhi, Kathleen M. Neuzil, Mari Kirsten, John C. Victor, Nigel A. Cunliffe, Cheryl Louw and Bagrey Ngwira and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Paul Gillard

48 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

2010 693 citations Shabir A. Madhi, Nigel A. Cunliffe et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Gillard Belgium	19	1.4k	829	664	623	413	49	2.1k
Aino Karvonen Finland	20	1.5k 1.0×	989 1.2×	837 1.3×	647 1.0×	290 0.7×	28	2.4k
Astrid Borkowski Switzerland	27	1.3k 0.9×	1.5k 1.8×	315 0.5×	129 0.2×	616 1.5×	50	2.7k
Kari Johansen Sweden	24	832 0.6×	518 0.6×	325 0.5×	179 0.3×	220 0.5×	38	1.5k
Karin Bok United States	29	2.4k 1.6×	262 0.3×	1.1k 1.7×	402 0.6×	95 0.2×	64	2.7k
Hans L. Bock Belgium	24	646 0.4×	999 1.2×	239 0.4×	526 0.8×	155 0.4×	76	1.7k
Margaret B. Rennels United States	29	1.0k 0.7×	1.5k 1.8×	450 0.7×	152 0.2×	149 0.4×	70	2.7k
Howard A. Fields United States	34	1.6k 1.1×	1.9k 2.3×	367 0.6×	2.9k 4.6×	177 0.4×	115	3.7k
Heli Harvala United Kingdom	32	1.8k 1.3×	1.5k 1.8×	1.9k 2.8×	183 0.3×	158 0.4×	94	2.9k
Elke Wollants Belgium	18	957 0.7×	449 0.5×	167 0.3×	230 0.4×	91 0.2×	44	1.5k
K Midthun United States	21	2.0k 1.4×	425 0.5×	880 1.3×	300 0.5×	82 0.2×	35	2.3k

Countries citing papers authored by Paul Gillard

Since Specialization

Citations

This map shows the geographic impact of Paul Gillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Gillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Gillard more than expected).

Fields of papers citing papers by Paul Gillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Gillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Gillard. The network helps show where Paul Gillard may publish in the future.

Co-authorship network of co-authors of Paul Gillard

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Gillard. A scholar is included among the top collaborators of Paul Gillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Gillard. Paul Gillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gillard, Paul, et al.. (2025). Enhancing vaccine clinical trials participation among elderly: challenges and strategies. Trials. 26(1). 38–38. 1 indexed citations

Coccia, Margherita, Wivine Burny, Marie‐Ange Demoitié, et al.. (2022). Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses. PLoS ONE. 17(11). e0276505–e0276505. 5 indexed citations

Habib, Md. Ahsan, Roman Prymula, Stéphane Carryn, et al.. (2021). Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. Vaccine. 39(25). 3445–3454. 8 indexed citations

Povey, Michael, et al.. (2020). Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children. Vaccine. 38(17). 3300–3304. 5 indexed citations

Lucidarme, Olivier, Mathilde Wagner, Paul Gillard, et al.. (2019). RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. Cancer Imaging. 19(1). 85–85. 9 indexed citations

Berg, Robert A. van den, Laurane De Mot, Geert Leroux‐Roels, et al.. (2018). Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults. Frontiers in Immunology. 9. 564–564. 28 indexed citations

Gillard, Paul, et al.. (2014). Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study. Trials. 15(1). 419–419. 5 indexed citations

Damme, Pierre Van, et al.. (2013). Long-term persistence of humoral and cellular immune responses induced by an AS03_A-adjuvanted H1N1 2009 influenza vaccine. Human Vaccines & Immunotherapeutics. 9(7). 1512–1522. 9 indexed citations

Gillard, Paul, Adrian Caplanusi, Markus Knuf, et al.. (2012). An assessment of prime‐boost vaccination schedules with AS03_A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza and Other Respiratory Viruses. 7(1). 55–65. 28 indexed citations

10.

Yang, Pan‐Chyr, Chong‐Jen Yu, Shan‐Chwen Chang, et al.. (2012). Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. Journal of the Formosan Medical Association. 111(6). 333–339. 8 indexed citations

11.

Duval, Xavier, Adrian Caplanusi, H. Laurichesse, et al.. (2012). Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial. BMC Infectious Diseases. 12(1). 162–162. 3 indexed citations

12.

Meulemeester, Marc De, Didier Giet, Giancarlo Icardi, et al.. (2011). Immunogenicity profile of a 3.75-Ug hemagglutinin pandemic rH5N1 split virion As03A-adjuvanted vaccine in elderly persons : a randomized trial. Open Repository and Bibliography (University of Liège). 3 indexed citations

13.

Meulemeester, Marc De, Didier Giet, Giancarlo Icardi, et al.. (2011). Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial. The Journal of Infectious Diseases. 203(8). 1054–1062. 27 indexed citations

14.

Ikematsu, Hideyuki, Hideaki Nagai, Masahiro Kawashima, et al.. (2010). Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Human Vaccines. 6(11). 888–893. 18 indexed citations

15.

Madhi, Shabir A., Nigel A. Cunliffe, A. Duncan Steele, et al.. (2010). Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. New England Journal of Medicine. 362(4). 289–298. 693 indexed citations breakdown →

16.

Leroux‐Roels, Isabel, François Roman, Cathy Maes, et al.. (2009). Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine. 28(3). 849–857. 114 indexed citations

17.

Vos, Béatrice De, Htay Htay Han, Alain Bouckenooghe, et al.. (2009). Live Attenuated Human Rotavirus Vaccine, RIX4414, Provides Clinical Protection in Infants Against Rotavirus Strains With and Without Shared G and P Genotypes. The Pediatric Infectious Disease Journal. 28(4). 261–266. 63 indexed citations

18.

Gillard, Paul. (2008). Immunogenicity Evaluation of an AS03-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3-9 Years. 46th Annual Meeting. 2 indexed citations

19.

Ballester, Alfredo, et al.. (2008). Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3–9 Years: A Phase II Study. International Journal of Infectious Diseases. 12. e146–e146. 7 indexed citations

20.

Baras, Benoı̂t, Jeanne‐Marie Devaster, Louis Fries, et al.. (2008). A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza and Other Respiratory Viruses. 2(6). 251–260. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact